News And Investors

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Corporate Profile

Chiasma develops and commercializes oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) technology to reduce the burden of chronic injections for people with rare diseases. Chiasma’s proprietary TPE® technology is designed to convert select peptide based injectables into oral formulations. By leveraging this technology, patients may be alleviated of the burdens associated with chronic injectable therapies.

Using its TPE® technology, Chiasma developed MYCAPSSA® (octreotide), a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Chiasma is headquartered in the United States with a wholly-owned subsidiary in Israel.
 

Latest Quarterly Earnings

Show all

2021

Q1
News Releases
Upcoming Events
There are no events available at this time.

You are about to review presentations, reports, filings, Q&A and/or other materials regarding Chiasma, Inc. (NASDAQ: CHMA) that contain time-sensitive information. The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Chiasma shareholders.

Chiasma expressly disclaims any obligation to review, update or correct these materials after the date thereof. Chiasma may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.

Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Chiasma's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Chiasma can be found in Chiasma's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and/or its most recent Quarterly Report on Form 10-Q.

This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users.  Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.

This information is intended for communication with investors and should not be construed as marketing the use of any Chiasma products or product candidates.

Information on this website may be revised without any prior notice.